COGNITION THERAPEUTICS INC (CGTX)

US19243B1026 - Common Stock

1.8  -0.02 (-1.1%)

News Image
2 days ago - InvestorPlace

CGTX Stock Earnings: Cognition Therapeutics Beats EPS for Q4 2023

CGTX stock results show that Cognition Therapeutics beat analyst estimates for earnings per share the fourth quarter of 2023.

News Image
2 days ago - BusinessInsider

CGTX Stock Earnings: Cognition Therapeutics Beats EPS for Q4 2023

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Cognition Therapeutics (NASDAQ:CGTX) just reported results for the fourth quart...

News Image
2 days ago - Cognition Therapeutics, Inc.

Cognition Therapeutics Reports Year End 2023 Financial Results and Provides Business Update

- Topline Results from SHINE Study in Mild-to-Moderate Alzheimer’s Expected mid-2024 -- On Track to Report Topline Results from SHIMMER Study in...

News Image
13 days ago - Cognition Therapeutics, Inc.

Cognition Therapeutics to Report Fourth Quarter and Full Year 2023 Results

Conference Call and Live Audio Webcast Scheduled for March 26, 2024

News Image
13 days ago - Cognition Therapeutics, Inc.

Cognition Therapeutics to Report Fourth Quarter and Full Year 2023 Results

Conference Call and Live Audio Webcast Scheduled for March 26, 2024...

News Image
14 days ago - Cognition Therapeutics, Inc.

Cognition Therapeutics Announces Closing of $11.5 Million Public Offering of Common Stock

PURCHASE, N.Y., March 14, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (“Cognition,” the “Company” or “We”) (Nasdaq: CGTX), a clinical stage...

News Image
17 days ago - Cognition Therapeutics, Inc.

Cognition Therapeutics Announces Pricing of $11.5 Million Public Offering of Common Stock

PURCHASE, N.Y., March 11, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (“Cognition,” the “Company” or “We”) (Nasdaq: CGTX), a clinical stage...

News Image
17 days ago - Chartmill

Top movers in Monday's after hours session

After the closing bell on Monday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session.

News Image
17 days ago - Cognition Therapeutics, Inc.

Cognition Therapeutics Announces Proposed Public Offering of Common Stock

PURCHASE, N. Y., March 11, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (“Cognition,” the “Company” or “We”) (Nasdaq: CGTX), a clinical stage...

News Image
22 days ago - Cognition Therapeutics, Inc.

Cognition Therapeutics Presents Analyses at AD/PD™ 2024 Correlating Proteomic Findings with Treatment Effect of CT1812 in Alzheimer’s Disease Studies

PITTSBURGH, March 06, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical stage company developing product candidates that...

News Image
a month ago - Cognition Therapeutics, Inc.

Cognition Therapeutics to Present at the TD Cowen Health Care Conference

PURCHASE, N.Y., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical stage company developing product candidates...

News Image
2 months ago - Cognition Therapeutics, Inc.

New Publication Identifies Key Proteins Involved in Amyloid Oligomer Binding and Supports Mechanism of CT1812

NEW YORK, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical stage company developing drugs that treat...

News Image
3 months ago - Cognition Therapeutics, Inc.

Cognition Therapeutics CEO Issues Letter to Shareholders

News Image
3 months ago - Cognition Therapeutics, Inc.

Cognition Therapeutics CEO Issues Letter to Shareholders

Topline data from Phase 2 SHINE trial in patients with mild-to-moderate Alzheimer's disease anticipated in mid 2024 Topline data from Phase 2 SHIMMER...

News Image
3 months ago - Seeking Alpha

Cognition Therapeutics files to sell 6.03M shares for holders (NASDAQ:CGTX)

Cognition Therapeutics (CGTX) files prospectus for resale of 6.03M shares. Not an offer to sell.

News Image
4 months ago - Cognition Therapeutics, Inc.

Cognition Therapeutics Releases New Episode of “Conversations” Podcast Recorded at CTAD with Quantitative EEG Experts, Drs Willem de Haan and Philip Scheltens

PURCHASE, N.Y., Nov. 16, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (Nasdaq: CGTX), (the “Company” or “Cognition”) has released its seventh...

News Image
4 months ago - Cognition Therapeutics, Inc.

Cognition Therapeutics Presents Preclinical Data Identifying Pathways Impacted by Sigma-2 Receptor Modulators in Alzheimer’s and Parkinson’s Diseases

NEW YORK, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX) is presenting in vivo preclinical results at the Society for...

News Image
5 months ago - Cognition Therapeutics, Inc.

Cognition Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

Phase 2 trials in mild-to-moderate Alzheimer’s disease and dementia with Lewy bodies advancing Clinical site initiation underway in 540-patient early...

News Image
5 months ago - Cognition Therapeutics, Inc.

Cognition Therapeutics and Collaborators at Yale and ACTC Announce Oral Late-breaking Presentation on the START Study in Early Alzheimer’s Disease at CTAD

NEW YORK, Oct. 27, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX) announced that Christoper van Dyck, M.D., the director of the...

News Image
5 months ago - Seeking Alpha

Prothena stock falls on Biogen's new Alzheimer’s drug

Prothena (PRTA) and BioVie (BIVI) stocks decline after Biogen (BIIB) and Eisai (ESAIY) reported positive data for their new Alzheimer's injectable. Read more here.